Compare PACK & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | PRTC |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.2M | 464.3M |
| IPO Year | 2017 | N/A |
| Metric | PACK | PRTC |
|---|---|---|
| Price | $4.15 | $17.19 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.17 | N/A |
| AVG Volume (30 Days) | ★ 443.0K | 3.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,900,000.00 | N/A |
| Revenue This Year | $9.47 | N/A |
| Revenue Next Year | $9.54 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | ★ 9.69 | N/A |
| 52 Week Low | $2.91 | $13.30 |
| 52 Week High | $6.51 | $20.00 |
| Indicator | PACK | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 45.70 |
| Support Level | $3.26 | $16.51 |
| Resistance Level | $6.01 | $18.10 |
| Average True Range (ATR) | 0.33 | 0.33 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 25.65 | 32.45 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.